1. Introduction {#s1}
===============

HIV disease continues to be a serious health issue for resource-limited countries like Ethiopia. According to the UNAIDS (2016) fact sheet, there were about 2.1 million new cases of HIV in 2015 globally ([@B1]). About 36.7 million people were living with HIV around the world, and, as of June 2016, 18.2 million people living with HIV were receiving medicine to treat HIV, called antiretroviral therapy (ART). An estimated 1.1 million people died from AIDS-related illnesses in 2015, and 35 million people have died from AIDS-related illnesses since the start of the epidemic. CD4^+^ cell counts are the primary targets of HIV. The relentless destruction of CD4^+^ cell counts by HIV, either directly or indirectly, results in the loss of HIV-specific immune responses and, finally, non-specific immune response in the AIDS stage. The estimation of peripheral CD4^+^ cell counts has been used as a tool for monitoring disease progression and the effectiveness of antiretroviral treatment (ART) ([@B2]). The changes in the CD4^+^ cell counts are important indicators of the response to ART. Initial CD4^+^ cell count, age, gender, smoking, unemployment, WHO stage, hospital, opportunistic infections, body mass index, changing doctors during outpatient follow up, use of alcohol and drugs, and duration of treatment (in months) are some of the significant determinants that affect CD4^+^ cell count progression of patients on ART ([@B3]--[@B5]).

Most studies conducted in the area fitted statistical models that require (multivariate) Normal distribution by considering CD4^+^ cell counts as continuous variable. When this assumption is violated, even after transformation, considering Poisson-related models is a natural choice. One of the common problems one can be faced with in analyzing count data like the CD4^+^ cell count is overdispersion. A Negative Binomial model can be considered to overcome this problem. Trindade et al. applied Poisson and Negative Binomial models using the multilevel (ML) approach and the generalized estimations equations (GEE) to model CD4^+^ cell counts of 587 HIV seropositive patients, and they stated that the best marginal model to fit the data was the Negative Binomial (NB) with an exchangeable correlation structure ([@B6]). Tekle et al. also employed different count data analysis methods starting from the ordinary Poisson regression model to study CD4^+^ cell counts of 222 HIV positive patients, and they found that Poisson-Normal-Gamma is the best model to fit their data ([@B7]). In this study, we applied various count data models to study the progression of the CD4^+^ cell count of HIV patients and identified risk factors for progression of patients\' CD4^+^ cell count in Debre Markos Referral Hospital, Ethiopia.

2. Materials and Methods {#s2}
========================

In practice, it is common to have response variables of a count type-like number of the CD4^+^ cell count in a cubic milliliter of blood. Some data analysts treat the CD4^+^ cell count as a continuous measure and apply the linear mixed effects model. But that practice ignores two facts: the data are really discrete, and the distributions of count variables are usually skewed. For these reasons, the use of models that assume (multivariate) normality might not be efficient ([@B8]). Even if the data is transformed and these models are applied, the interpretation might not be straightforward. In scenarios like this, it is better to apply statistical models that account for the nature of the data.

Our data includes 445 HIV-positive patients who started ART treatment between December 2005 and July 2014 in Debre Markos Referral Hospital, Ethiopia. The minimum number of measurements was two and the maximum was seven. Patients with less than two measurements and age of \<15 years were excluded from the study.

For our data, the assumption of multivariate normality failed, and this suggested that use of a linear mixed model was not appropriate ([Table 1](#T1){ref-type="table"}). The Poisson regression model with normal random effects and models that account for both correlation between repeated measures and overdispersion simultaneously were thus considered in line with Booth et al. ([@B9]) and Molenberghs et al. ([@B10], [@B11]).

###### 

Multivariate normality test.

  **Test**                **Value**   ***P*-value**   **Result**
  ----------------------- ----------- --------------- ----------------------------------
  Henze-Zirkler\'s test   1.099       \< 0.0001       Data are not multivariate normal
  Mardia\'s test                                      Data are not multivariate normal
     Skewness (22.51)     138.842     0.0002          
     Kurtosis (71.24)     2.231       0.0257          
  Royston\'s test         25.294      0.0002          Data are not multivariate normal

2.1. Variables in the Study
---------------------------

### 2.1.1. Dependent Variable

The dependent variable of this study was the CD4^+^ cell count per cubic millimeter of blood of HIV-infected patients who are under ART treatment.

### 2.1.2. Independent Variables

The independent variables considered in this study were selected based on related literature ([@B5], [@B7]). These include the sex of patients, age of patients (age at the initiation of the treatment), baseline CD4^+^ cell count (the CD4^+^ cell count of the patients at the start of the treatment), WHO clinical stage at baseline (stage I, stage II, stage III, and stage IV), marital status at baseline, baseline weight, level of education at baseline, functional status at baseline, TB status at baseline, and time in months. Functional status was defined as WHO categories: Ambulatory and Working. Patients who are able to perform activities of daily living but not able to work or play are classified as ambulatory and the who are able to perform usual work in or out of the house, harvest, go to school or for children, normal activities, or playing were classified as working.

2.2. Poisson Model
------------------

Let *Y*~*i*~ be the ith CD4^+^ cell count and is Poisson distributed with mean λ~*i*~. The density function of *Y*~*i*~ can then be written as
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The Poisson distribution belongs to the exponential family, with natural parameter θ~*i*~ equal to lnλ~*i*~, scale parameter ϕ = 1, and variance function *v*(λ~*i*~) = λ~*i*~ ([@B12]). The logarithm is the natural link function, leading to the classical Poisson regression model *Y*~*i*~ \~ *Poisson*(λ~*i*~), with $\log{(\lambda_{i})} = X_{i}^{T}\beta$.

2.3. Poisson-Gamma Model
------------------------

The standard Poisson distribution requires the mean and variance to be equal. When this assumption fails, the Poisson-Gamma model should be used to fit the data. Assume that *Y*~*i*~\|θ~*i*~ \~ *Poi*(θ~*i*~λ~*i*~), where θ~*i*~ denotes an independent and identically distributed (iid) sample of unit mean Gamma random variables with shape parameter α ([@B9]). Conditional on θ~*i*~, the CD4 count of the *i*th patient follows a Poisson distribution with mean θ~*i*~λ~*i*~. The counts are then marginally independent Poisson-Gamma random variables \[*Y*~*i*~ \~NB(α, λ~*i*~)\] with mean λ~*i*~ and variance $\lambda_{i} + \lambda_{i}^{2}/\alpha$. Hence, the parameter α quantifies the amount of overdispersion with α = ∞ corresponding to no overdispersion with respect to the Poisson distribution. The mass function of the Poisson-Gamma random variables is given by
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The Poisson-Gamma model (also known as the Negative Binomial model) is given by $\log{(\lambda_{i})} = X_{i}^{T}\beta$.

2.4. Poisson-Normal Model
-------------------------

For μ~*ij*~ =E(*Y*~*ij*~\|*b*~*i*~) and known link function η(.), the generalized linear mixed model can be expressed as:
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where *Y*~*ij*~ is the CD4^+^ cell count of the *i*th patient at *j*th visit (measurement). β= a p-dimensional vector of unknown fixed regression coefficients. *b*~*i*~ = a q-dimensional vector of unknown random regression coefficients for the ith individual, and these are often assumed to be drawn independently from the N(0, D), and D is the variance-covariance matrix of the random effects. *X*~*ij*~ and *Z*~*ij*~ are p-dimensional and q-dimensional vectors of known covariate values, respectively ([@B10]). The generalized mixed Poisson model with normal random effects (Poisson-Normal model) becomes
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This model is referred to as the Poisson-Normal model because it assumes Poisson distribution for the counts and normal distribution for the random effects *b*~*i*~ ([@B10], [@B11]).

2.5. Poisson-Gamma-Normal Model
-------------------------------

According to Molenberghs et al. ([@B10], [@B11]), a model combining the ideas from the Poisson-Normal and overdispersion models for repeated Poisson data with overdispersion can be specified as follows *Y*~*ij*~ \~ *poi*(θ~*ij*~λ~*ij*~)
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where θ~*ij*~ capture overdispersion and denote an independent and identically distributed (iid) sample of unit mean gamma random variables with shape parameter α and scale parameter β=1/α, and where *b*~*i*~ \~ *N*(0, *D*) and θ~*ij*~ \~ *Gamma*(α, β). This model is called the Poisson-Gamma-Normal (combined) model because it includes both Normal (*b*~*i*~) and Gamma (θ~*ij*~) random effects to account for correlation and overdispersion, respectively.

2.6. Methods of Parameter Estimation
------------------------------------

In this study, we used glmer and glmer.nb functions in R under packages MASS and lme4. A Laplace approximation was used to obtain parameter estimates. The R code used to fit the models is available in [Supplementary Material](#SM1){ref-type="supplementary-material"}.

2.7. Model Comparison
---------------------

To select the important variables, first the main effect, main effect by time interaction, and plausible main effect by main effect interactions were incorporated to the initial candidate models, the non-significant interaction effects were then removed, and the models were refitted again and so on. The best model that can fit the data was selected using various information criteria (AIC, BIC, and −2loglikelihood) (**Table 7**). The model with smallest values of information criteria was selected as the final model.

3. Results and Discussion {#s3}
=========================

3.1. Descriptive Analysis
-------------------------

In this section, CD4^+^ cell count data obtained from 445 HIV patients on ART treatment in Debre Markos Referral Hospital were summarized. The majority of the HIV patients \[347 (78.0%)\] started antiretroviral treatment with CD4^+^ cell counts \<200 cells/mm^3^. At the start of the treatment, the median CD4^+^ cell count of the patients was 145 CD4^+^ cells/mm^3^ of blood with IQR of 107.00 CD4^+^ cells/*mm*^3^ of blood. The minimum and maximum baseline CD4^+^ cell counts were three and 971 CD4^+^ cell cells/mm^3^ of blood, respectively.

The summary of CD4^+^ cell counts at different time points is given in [Table 2](#T2){ref-type="table"}. As can be seen in [Table 2](#T2){ref-type="table"}, the median CD4^+^ cell count increased over time. The IQR of CD4^+^ cell counts increased at some points and then started to decrease after the 24th month. The number of patients decreased at some points and increased at others, which implies the presence of intermittent missingness in the data. That means some patients were falling out of care and then re-engaging, or they did not have CD4^+^ cell counts that were spaced perfectly every 6 months.

###### 

Summary of CD4^+^ cell count at different time points.

  -------------- --------------- ---------------------- -------------------- -------------------- -------------------- -------------------- ----------------
  Time           0               6                      12                   18                   24                   30                   36
  *n*            445             372                    320                  283                  271                  279                  261
  Median         145             260                    302                  323                  342                  357                  371
  IQR (Q1, Q3)   107 (85, 192)   206.25 (177, 383.25)   201.5 (204.5, 406)   258.5 (216.5, 475)   274 (234.5, 508.5)   220.5 (261, 481.5)   209 (272, 481)
  -------------- --------------- ---------------------- -------------------- -------------------- -------------------- -------------------- ----------------

Data on demographic and clinical characteristics of the patients was collected at the start of antiretroviral treatment. Among the 445 patients, 280 (62.9%) were females. The male patients had a 134.84 mean baseline CD4^+^ cell count, while the female patients had a mean baseline CD4^+^ cell count of 168.91. On average, female patients started ART treatment at a relatively higher CD4^+^ cell count. The difference in mean CD4^+^ cell count of the two groups increases as time increases. The average CD4^+^ cell count of females was higher than males at all time points and the difference increases over time.

WHO stage III had a higher number of patients \[282 (63.4%)\] as compared to the other three stages. WHO stage II took second place in number of patients \[77 (17.3%)\], and WHO stage IV had the smallest number of patients \[27 (6.1%)\]. As expected, patients on WHO stage I had a higher CD4^+^ cell count at all time points as compared to patients of the other three stages of the disease.

Patients with a working functional status have a higher mean CD4^+^ cell count at all time points than that of patients with ambulatory functional status. Among the 445 HIV patients included in this study, 346 (77.8%) were patients with working functional status and 99 (22.3%) were ambulatory ([Table 3](#T3){ref-type="table"}). About 27.3% of the 445 HIV patients were TB positive at baseline. TB negative patients had a higher mean CD4^+^ cell count at all time points compared to TB positive patients, implying the impact of the HIV-TB coinfection.

###### 

Summary of CD4^+^ cell count progression for some categorical covariates.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                      **Time (in months)**                                                                                                                            
  ------------------- ---------------------- ---------- --------------- ------------------ ------------------ ------------------ ----------------- ------------------ ----------------
  Sex                                                                                                                                                                 

                      Male                   *n*        165             131                117                100                97                106                106

                                             Median     130.0           235.0              250.0              295.5              297.0             312.0              318.0

                                             IQR\       112\            177\               187\               255.25\            270\              209.5\             188.75\
                                             (Q1, Q3)   (62, 174)       (165, 342)         (172, 359)         (170, 425.25)      (181, 451)        (210.25, 419.75)   (238, 426.75)

                      Female                 *n*        280             241                203                183                174               173                155

                                             Median     155.5           275.0              324.0              331.0              376.5             377.0              418.0

                                             IQR\       110\            204\               216\               258.5\             293.5\            226\               250.5\
                                             (Q1, Q3)   (92, 202)       (191, 395)         (227.5, 443.5)     (236, 494.5)       (257, 550.5)      (289, 515)         (301.5, 552)

  WHO stage                                                                                                                                                           

                      Stage I                *n*        59              51                 41                 36                 38                35                 36

                                             Median     187.0           300.0              349.0              444.5              446.0             317.0              396.0

                                             IQR\       145.5\          283\               308\               288.25\            333.75\           209\               290.5\
                                             (Q1, Q3)   (131, 276.5)    (216.5, 499.5)     (243, 551)         (326.5, 614.75)    (257, 590.75)     (285, 494)         (323.5, 614)

                      Stage II               *n*        77              65                 54                 52                 47                48                 42

                                             Median     130.0           229.0              267.5              261.5              297.0             351.5              332.0

                                             IQR\       96\             187\               160.75\            214.25\            229.5\            193.25\            164.75\
                                             (Q1, Q3)   (83, 179)       (156, 343)         (189.5, 350.25)    (158.75, 373)      (175, 404.5)      (251.5, 444.75)    (245, 409.75)

                      Stage III              *n*        282             235                208                175                171               173                165

                                             Median     143.0           258.0              314.0              322.5              342.0             363.0              381.0

                                             IQR\       106.75\         180.75\            199\               268\               255.5\            225\               211.5\
                                             (Q1, Q3)   (83.25, 190)    (179.25, 360)      (206, 405)         (202.25, 470.25)   (243.5, 499)      (256, 481)         (262, 473.5)

                      Stage IV               *n*        27              21                 17                 20                 15                23                 18

                                             Median     114.0           319.5              246.5              343.0              380.0             361.0              434.0

                                             IQR\       123\            276\               200.75\            263\               376.5\            229\               269\
                                             (Q1, Q3)   (49.5, 172.5)   (150.75, 426.75)   (153.75, 354.50)   (230, 493)         (219, 595.5)      (257, 486)         (283, 552)

  Functional status                                                                                                                                                   

                      Working                *n*        346             291                256                214                210               220                211

                                             Median     157.0           270.0              305.5              324.0              350.5             362.0              371.0

                                             IQR\       105.75\         199\               191.25\            237.75\            258.75\           199.75\            196\
                                             (Q1, Q3)   (97.25, 203)    (186, 385)         (215.75, 407)      (236.25, 474)      (257, 515.75)     (282.75, 482.5)    (283.5, 479.5)

                      Ambulatory             *n*        99              81                 64                 69                 61                59                 50

                                             Median     98.0            232.0              271.5              275.0              290.0             310.0              380.0

                                             IQR\       96\             232\               246.25\            315\               302\              253.5\             236\
                                             (Q1, Q3)   (55, 151)       (128, 360)         (159.75, 406)      (161, 476)         (169, 471)        (218.5, 472)       (245.5, 481.5)

  TB status                                                                                                                                                           

                      Negative               *n*        368             311                268                232                231               225                213

                                             Median     150.0           266.0              306.5              329.5              342.0             357.0              371.0

                                             IQR\       107\            205\               203\               261.25\            286.5\            209\               190\
                                             (Q1, Q3)   (85, 192)       (180, 385)         (212, 415)         (220.75, 482)      (236, 522.5)      (270, 479)         (281, 471)

                      Positive               *n*        77              61                 52                 51                 40                54                 48

                                             Median     132.0           241.0              253.5              297.0              348.5             367.5              404.0

                                             IQR\       98\             202\               207.5\             214\               286.25\           242\               273\
                                             (Q1, Q3)   (84, 182)       (162, 364)         (162, 369.5)       (176, 390)         (179.5, 465.75)   (240.5, 482.5)     (250, 523)
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

3.2. Exploratory Data Analysis
------------------------------

[Figure 1](#F1){ref-type="fig"} depicts the individual profile plot of the CD4^+^ cell count of HIV-infected patients included in the study. The plot provides some information on the between patients\' CD4^+^ cell count variability and illustrates the over-time change in patients\' CD4^+^ cell count. Some individuals have an erratic CD4^+^ cell count and others have a CD4^+^ cell count that slowly increases over time. As one can see from the graph, there is a considerably large difference in the intercepts of individual trajectories. Similarly, some trajectories are steeper, while others were almost horizontal, indicating the possible variability in the slope of CD4^+^ cell counts. Therefore, because of the variability in the intercept and slope of trajectories, using a mixed model could fit the data very well. The overall mean profile plot of the CD4^+^ cell count shows somehow a linear increasing pattern of CD4^+^ cell count over time ([Figure 2](#F2){ref-type="fig"}), suggesting that a linear time effect seems reasonable. The mean CD4^+^ cell count increases at a high rate from baseline till the 6th month and then starts to increase slowly from 6 to 24th month and decreases at month 30.

![The individual profile plot of CD4 count.](fpubh-07-00415-g0001){#F1}

![The overall mean profile plot of CD4 cell count.](fpubh-07-00415-g0002){#F2}

3.3. Model Results
------------------

[Table 4](#T4){ref-type="table"} summarizes the parameter estimates of Poisson and Poisson-Gamma regression models employed on the CD4^+^ cell count. All parameters included in the Poisson regression model are significant at 5% level of significance. For this study, the data were overdispersed, as the sample variance of CD4^+^ cell count at all time points was greater than its corresponding sample means ([Table 2](#T2){ref-type="table"}). A likelihood ratio (LR) test was used to test the null hypothesis that the restriction in the Poisson model was true. The test revealed that the null hypothesis was rejected, implying the presence of overdispersion in our data. The Poisson-Gamma model better fits the data as compared to the Poisson model with smallest AIC value. The Poisson-Normal model with both random intercept and slope was found to be the best fit since it has smaller information criteria values compared with the only random intercept model. The parameter estimates of this model are displayed in [Table 5](#T5){ref-type="table"}. Depending on this model time, the WHO stage and initial CD4^+^ cell count were found to be significant factors of patients\' CD4^+^ cell count progression.

###### 

Poisson and Poisson-Gamma models.

                                          **Poisson**   **Poisson-Gamma**                                 
  --------------------------------------- ------------- ------------------- ---------- --------- -------- ----------
  Intercept                               4.6438        0.0118              \<0.0001   4.5387    0.0954   \<0.0001
  Time                                    0.0201        0.0001              \<0.0001   0.0248    0.0008   \<0.0001
  Sex (Ref. = Male)                                                                                       
     Female                               0.1418        0.0032              \<0.0001   0.1069    0.0260   \<0.0001
  Marital status (Ref. = Divorced)                                                                        
     Married                              0.0632        0.0031              \<0.0001   0.0110    0.0255   0.6647
     Never                                0.1290        0.0047              \<0.0001   0.0853    0.0382   0.0256
     Widowed                              0.0508        0.0039              \<0.0001   0.0065    0.0319   0.8398
  Level of education (Ref. = Secondary)                                                                   
     No                                   0.0264        0.0033              \<0.0001   0.0157    0.0267   0.5577
     Primary                              −0.0066       0.0034              0.0544     −0.0005   0.0273   0.9857
     Tertiary                             0.0565        0.0046              \<0.0001   0.0245    0.0386   0.5257
  Functional status (Ref. = Ambulatory)                                                                   
     Working                              0.0067        0.0033              0.0457     −0.0123   0.0263   0.6397
  WHO stage (Ref. = Stage II)                                                                             
     Stage I                              0.0281        0.0046              \<0.0001   0.0204    0.0377   0.5882
     Stage III                            0.1125        0.0035              \<0.0001   0.0989    0.0279   0.0004
     Stage IV                             0.0257        0.0058              \<0.0001   0.0061    0.0473   0.8968
  TB status (Ref. = Positive)                                                                             
     Negative                             0.0477        0.0034              \<0.0001   0.0570    0.0272   0.0364
  Age                                     −0.0038       0.0001              \<0.0001   −0.0033   0.0011   0.0040
  Weight                                  0.0036        0.0002              \<0.0001   0.0021    0.0013   0.1066
  Base CD4                                0.0024        0.0000              \<0.0001   0.0034    0.0001   \<0.0001
  Dispersion parameter (1/α)                                                           4.666     0.139    
  AIC                                     145,787                                      27,848             

###### 

Poisson-Normal model.

                                          **Random intercept only**   **Random intercept and slope**                                    
  --------------------------------------- --------------------------- -------------------------------- ----------- ----------- -------- -----------
  Intercept                               4.5063                      0.1637                           \< 0.0001   4.2967      0.1514   \< 0.0001
  Time                                    0.0211                      0.0001                           \< 0.0001   0.0243      0.0008   \< 0.0001
  Sex (Ref. = Male)                                                                                                                     
     Female                               0.1242                      0.0451                           0.0060      0.0767      0.0422   0.0692
  Marital status (Ref. = Divorced)                                                                                                      
     Married                              0.0175                      0.0443                           0.6921      0.0204      0.0408   0.6165
     Never                                0.1004                      0.0656                           0.1260      0.0881      0.0607   0.1464
     Widowed                              0.0340                      0.0554                           0.5393      0.0543      0.0510   0.2876
  Level of education (Ref. = Secondary)                                                                                                 
     No                                   −0.02109                    0.0463                           0.6487      0.0178      0.0427   0.6768
     Primary                              −0.0255                     0.0474                           0.5901      0.0164      0.0437   0.7068
     Tertiary                             −0.0282                     0.0663                           0.6702      0.0099      0.0611   0.8710
  Functional status (Ref. = Ambulatory)                                                                                                 
     Working                              −0.0036                     0.0449                           0.9357      0.0456      0.0415   0.2721
  WHO stage (Ref. = Stage II)                                                                                                           
     Stage I                              0.0361                      0.0651                           0.5791      −0.0092     0.0600   0.8779
     Stage III                            0.1194                      0.0479                           0.0126      0.0964      0.0442   0.0292
     Stage IV                             −0.2138                     0.0631                           0.0007      −0.0666     0.0622   0.2844
  TB status (Ref. = Positive)                                                                                                           
     Negative                             0.0730                      0.0470                           0.1205      0.0671      0.0434   0.1217
  Age                                     −0.0027                     0.0020                           0.1726      −0.0028     0.0018   0.1224
  Weight                                  0.0022                      0.0022                           0.3238      0.0031      0.0020   0.1354
  Base CD4                                0.0033                      0.0002                           \< 0.0001   0.0039      0.0002   \< 0.0001
  AIC                                     71,331.7                                                                 59,073.9             
  BIC                                     71,434.5                                                                 59,188.1             
  logLik                                  −35,647.8                                                                −29,516.9            
  Random intercept variance               0.1289                                                                   0.1203               
  Random slope variance                                                                                            0.0003               
  Cov (random effects)                                                                                             −0.32                

An improvement in both the Poisson-Gamma and Poisson-Normal models as compared with the Poisson model in fitting the data is an indication of the occurrence of both correlation and overdispersion in the data. The Poisson-Gamma-Normal (Negative Binomial log-linear mixed) model proposed by Booth et al. ([@B9]) and Molenberghs et al. ([@B10], [@B11]) was fitted to overcome this problem of correlated and overdispersed count data, and the random intercept Poisson-Gamma-Normal Model is a much better fit because of its lower AIC (27,379.9), BIC (27,488.4), and −2loglikelihood (27,342) values as compared to the Poisson-Normal models ([Table 6](#T6){ref-type="table"}). Therefore, the final model to fit our data was the random intercept Poisson-Gamma-Normal model. We have also tried the Poison-Gamma-Normal model with different (random) linear slopes for a time, but we found that the Poison-Gamma-Normal with random intercept was better based on information criteria (AIC and BIC).

###### 

Poisson-Gamma-Normal model.

                                          **Random intercept only**   **Random intercept and slope**                                    
  --------------------------------------- --------------------------- -------------------------------- ----------- ----------- -------- -----------
  Intercept                               4.4105                      0.1555                           \< 0.0001   4.3591      0.1078   \< 0.0001
  Time                                    0.0243                      0.0007                           \< 0.0001   0.0239      0.0010   \< 0.0001
  Sex (Ref. = Male)                                                                                                                     
     Female                               0.1147                      0.0427                           0.0073      0.0743      0.0295   0.0117
  Marital status (Ref. = Divorced)                                                                                                      
     Married                              0.0173                      0.0419                           0.6790      0.0183      0.0289   0.5277
     Never                                0.1024                      0.0623                           0.1001      0.0903      0.0430   0.0358
     Widowed                              0.0406                      0.0524                           0.4390      0.0424      0.0362   0.2424
  Level of education (Ref. = Secondary)                                                                                                 
     No                                   −0.0012                     0.0438                           0.9787      0.0256      0.0302   0.3955
     Primary                              −0.0052                     0.0449                           0.9070      0.0188      0.0312   0.5475
     Tertiary                             0.0039                      0.0630                           0.9507      0.0004      0.0432   0.9928
  Functional status (Ref. = Ambulatory)                                                                                                 
     Working                              0.0139                      0.0427                           0.7456      0.0282      0.0298   0.3448
  WHO stage (Ref. = Stage II)                                                                                                           
     Stage I                              0.0260                      0.0616                           0.6726      −0.0055     0.0424   0.8976
     Stage III                            0.0989                      0.0455                           0.0299      0.0870      0.0314   0.0056
     Stage IV                             −0.0136                     0.0773                           0.8607      −0.0257     0.0544   0.6364
  TB status (Ref. = Positive)                                                                                                           
     Negative                             0.0661                      0.0446                           0.1385      0.0525      0.0310   0.0898
  Age                                     −0.0027                     0.0019                           0.1440      −0.0028     0.0013   0.0286
  Weight                                  0.0023                      0.0021                           0.2721      0.0027      0.0014   0.0612
  Base CD4                                0.0034                      0.0002                           \< 0.0001   0.0039      0.0001   \< 0.0001
  Dispersion parameter (1/α)              7.7009                                                                   7.7009               
  AIC                                     27,379.9                                                                 27,487.7             
  BIC                                     27,488.4                                                                 27,607.6             
  logLik                                  −13,671.0                                                                −13,722.8            
  Random intercept variance               0.08837                                                                  0.0000               
  Random slope variance                                                                                            0.00025              
  Cov (random effects)                                                                                             0                    

Based on the results obtained from the Poisson-Gamma-Normal model, time in months, sex, and baseline CD4^+^ cell count were found to be significant factors of the CD4^+^ cell count of a patient ([Table 8](#T8){ref-type="table"}). For a given patient, keeping the random intercept and other covariates constant, one more month on ART increased the CD4^+^ cell count by a multiplicative factor of *e*^0.0243^ = 1.0246.

###### 

Summary of information criteria of different models.

             **Models**                       
  ---------- ------------ ---------- -------- ----------
  AIC        145,787      59,073.9   27,848   27,379.9
  BIC        145,884      59,188.1   27,951   27,488.4
  −2logLik   145,754      59,033.8   27,812   27,342

###### 

Poisson-Gamma-Normal model.

                                          **Random intercept only**            
  --------------------------------------- --------------------------- -------- -----------
  Intercept                               4.4105                      0.1555   \< 0.0001
  Time                                    0.0243                      0.0007   \< 0.0001
  Sex (Ref. = Male)                                                            
     Female                               0.1147                      0.0427   0.0073
  Marital status (Ref. = Divorced)                                             
     Married                              0.0173                      0.0419   0.6790
     Never                                0.1024                      0.0623   0.1001
     Widowed                              0.0406                      0.0524   0.4390
  Level of education (Ref. = Secondary)                                        
     No                                   −0.0012                     0.0438   0.9787
     Primary                              −0.0052                     0.0449   0.9070
     Tertiary                             0.0039                      0.0630   0.9507
  Functional status (Ref. = Ambulatory)                                        
     Working                              0.0139                      0.0427   0.7456
  WHO stage (Ref. = Stage II)                                                  
     Stage I                              0.0260                      0.0616   0.6726
     Stage III                            0.0989                      0.0455   0.0297
     Stage IV                             −0.0136                     0.0773   0.8607
  TB status (Ref. = Positive)                                                  
     Negative                             0.0661                      0.0446   0.1385
  Age                                     −0.0027                     0.0019   0.1440
  Weight                                  0.0023                      0.0021   0.2721
  Base CD4                                0.0034                      0.0002   \< 0.0001
  Dispersion parameter (1/α)              7.7009                               
  Random intercept variance               0.08837                              

A female patient had a CD4^+^ cell count of 1.1215 times that of a male patient, adjusting for other covariates and random intercept. A unit change in baseline CD4^+^ cell count increased the CD4^+^ cell count of a patient by a factor of 1.0034, fixing the values of the other covariates and the random intercept constant.

The dispersion parameter (1/α) has been estimated, in the final model, as 7.7009, and the Gamma (overdispersion) random effects are assumed to follow a Gamma distribution with unit mean and shape parameter α (0.130).

3.4. Discussion
---------------

The effects of demographic and clinical factors on the progression of CD4^+^ cell counts over time of HIV patients taking ART treatment in Debre Markos Referral Hospital were assessed using Poisson longitudinal models since the response variable of interest CD4^+^ cell count is a count variable.

The results of the summary statistics revealed that the value of IQR is high at all time points, which might be an indication for high variation among the patients\' CD4^+^ cell count at baseline as well as at different time points after the initiation of ART treatment. This variation might have been caused by the year at which the patients started ART treatment, as there have been different WHO\'s CD4^+^ cell count cut-off points to initiate ART treatment at different times. Although most of the patients included in our study started with lower CD4^+^ cell counts (\<200 cells/mm^3^), there were patients who had higher baseline CD4^+^ cell counts (971 cells/mm^3^). Despite the continuous effort to initiate early, some patients still presented with lower CD4^+^ cell counts, which might be due to patients\' lack of willingness to get tested ([@B13], [@B14]) or difficulties to provide treatments to all patients in lower-income countries including Ethiopia. Hence, we believe that our result could be generalizable. The final model also indicated that initial CD4^+^ cell count (CD4^+^ cell count at the start of the treatment) significantly affects CD4 count progression. Therefore, based on our findings we recommend patients to start the treatment early as of the WHO\'s "treat all" recommendation.

The sign of the parameter estimate of WHO stage III is positive, which implies that a patient with WHO stage III has a higher CD4^+^ cell count as compared with a patient of WHO stage II. It might be because the number of patients with WHO stage III are much higher (non-comparable) than patients with WHO stage II. The relationship between CD4^+^ cell count and WHO stage III might also be explained by the baseline CD4^+^ cell count. Duration of treatment also have a positive effect on the CD4^+^ cell count progression of HIV patients. This means patients with longer time on ART treatment have good recovery of CD4^+^ cell count than that of patients with short duration on the treatment.

4. Conclusion {#s4}
=============

An analysis of CD4^+^ cell count data using conventional models like linear mixed models might be inadequate as the data were highly skewed and may not satisfy normality (multivariate) assumption as demonstrated in our data.

In this study, CD4^+^ cell count data of 445 HIV patients under ART in Debre Markos Referral Hospital was analyzed using different longitudinal count models, and the Poisson-Gamma-Normal model was selected as the final model to fit the data based on different selection criteria. The Poisson-Gamma-Normal model handles overdispersion and correlation simultaneously.

The duration on ART treatment (time in months), sex of patients, and baseline CD4^+^ cell count were all identified as potential risk factors of CD4^+^ cell count progression. Having a good CD4^+^ cell count at baseline had a positive impact on CD4^+^ cell count evolution over time.

Although good CD4^+^ cell count progress in response to ART was observed, most of the patients (78.0%) were at decreased CD4^+^ cell counts (\<200 cells/mm^3^) when enrolled for ART treatment, which might have contributed to low CD4^+^ count recovery in some patients.

5. Limitations and Recommendation {#s5}
=================================

In our study, we only considered patients from one hospital. The likelihood inference of the models considered in this study are valid under MCAR (missing completely at random). In the current study, we did not carry out a sensitivity analysis, and we only considered linear slopes models, although a different linear slope for different time periods seems reasonable. Hence, we recommend that researchers consider sensitivity analysis and data obtained from different Hospitals. The age and weight of patients might have a non-linear relationship with the CD4^+^ cell count. We recommend smoothing techniques like splines to be explored for further studies. The assumption of multivariate normality that is assumed by most statistical models used in longitudinal data analysis should be checked before analysis. Efficient methods like the ones used in this study could be considered if the assumption is violated.
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